Document is current

Article History

Received: 8 May 2024

Accepted: 9 December 2024

First Online: 16 December 2024

Declarations

:

: J.A. reports lectures fees from Boehringer Ingelheim, AstraZeneca, MSD, Bayer, and Novartis, support for abstract presentation from Novartis, and advisory board reimbursement from AstraZeneca and Novartis. T.A. reports speakers’ honoraria from AstraZeneca, Vifor Pharma, Boehringer Ingelheim and Pharmacosmos, and participation on advisory boards for Vifor Pharma and Pharmacosmos. E.H. reports support from Uppsala University, , small personal fees from AMGEN, NovoNordisk, Bayer, AstraZeneca, fees for charing the Swedish secondary prevention registry and work as national coordinator for DalCore. M.L. reports payments from Bonnier Health Care, payments for pectures and educational events from AstraZeneca, NovoNordisk, Amarin, and Amgen as well as being principal investigator for the AstraZeneca DAPA-MI study in Malmö. J.S. reports, speaker honoraria from Bayer, AstraZeneca, Medtronics, Boehringer Ingelheim, Novo Nordisk, being president of the Swedish Society for Hypertension, Stroke and Vascular Medicine, the Swedish representative and advisory board member for VAS (Vascular Independent Research and Education European Organisation), and being a minor shareholder in Beat Vascular Health. S.S reports speakers’ honoraria from Actelion Ltd and support for meetings from Actelion Ltd. The rest of the authors declare no conflicts of interest.